Endonovo Therapeutics Issued Broad US Patent Covering Electromagnetic Treatment for MS

The United States Patent and Trademark Office (USPTO) has issued a patent to Endonovo Therapeutics for Application No. 15/549,748, which covers the company’s technique and device for electromagnetic treatment of multiple sclerosis (MS).

Endonovo has a pipeline of “Electroceuticals” — wearable, electronic, non-invasive therapeutic devices. These devices use pulsed electromagnetic fields (PEMF) to stimulate the central nervous system (CNS) in some disorders, like MS, and also to address wound healing, pain, edema, cardiovascular disease, and chronic kidney disease, among others. 

They work by restoring critical electrochemical processes associated with anti-inflammatory and growth factor responses necessary for healing. 

Endonovo’s Electroceuticals therapeutic system SofPulse, in particular, has been shown to speed the healing process and reduce the need for pain medications. The device also is of benefit in the treatment of inflammatory conditions, including neuroinflammatory diseases such as MS.

In fact, preliminary research in the field of autoimmune encephalomyelitis — an inflammatory autoimmune disease model, mimicking MS in humans — revealed that the device induces a significant reduction in disease severity when compared with placebo treatments in animals.

“This issuance follows our prior patents related to the methods of treating post-operative pain and edema,” Nev Zubcevik, DO, Endonovo’s chief medical officer and a physical medicine and rehabilitation specialist, said in a press release.

SofPulse has been previously cleared by the U.S. Food and Drug Administration (FDA) and CE marked in Europe as a medical device for the palliative treatment of soft tissue injuries and post-surgical pain and swelling (edema). Use of the device also has CMS National Coverage for the treatment of chronic injuries.

“We are looking forward to expanding our technology applications into neuroinflammatory disorders; we believe our growing patent portfolio reinforces Endonovo’s leadership position in utilizing SofPulse to address pain while also underscoring the pioneering nature of the company’s Pulsed Electromagnetic Field-based (PEMF) Electroceuticals,” Zubcevik added.

The SofPulse uses microcurrents that emit gentle pulses to the affected tissue as a means of redirecting the natural signals produced by the CNS. This restores key electrochemical processes and initiates anti-inflammatory pathways to alleviate or mitigate symptoms of brain injury and accelerate the biological recovery process.

According to Endonovo, microcurrents are safe, and the ones applied by its devices are in fact 1,000 times lower than those transmitted by a cellphone. Thus, treatment using SofPulse is safer, as it allows improved pain management without any of the side effects associated with the use of narcotics and anti-inflammatories.

“Our platform provides a unique opportunity for understanding the benefits Electroceuticals can deliver in a wide range of areas. Over the course of the past three years, Endonovo has grown its intellectual property in a rapid and methodical manner and we believe well positions us to extend our advantage in harnessing the power of Pulsed Electromagnetic Field (PEMF) Electroceuticals,” said Alan Collier, CEO of Endonovo.